Botanix Pharmaceuticals Company Description

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States.

Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis.

Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.

Botanix Pharmaceuticals Limited

Country	Australia
Founded	1984
Industry	Biotechnology
Sector	Healthcare
Employees	11
CEO	Howie McKibbon

Contact Details

Address: 41 – 47 Colin Street West Perth, 6005 Australia
Phone	61 8 6555 2945
Website	botanixpharma.com

Stock Details

Ticker Symbol	BOT
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU000000BOT2
SIC Code	2836

Key Executives

Name	Position
Dr. Howie McKibbon	Chief Executive Officer
Vincent P. Ippolito	MD and Executive Chairman
Graeme Morissey	Chief Financial Officer
Matthew Callahan L.L.B., M.B.A., MBA LLB	Executive Director
Dr. Jack Hoblitzell Ph.D.	Senior Vice President of Pharmaceutical Development
Dr. Patricia S. Walker M.D., Ph.D.	Chief Medical Adviser
Dr. Boris Meyerson Ph.D.	Chief Business Officer
David Morgan	Head of Corporate Affairs
Kevin Wojciechowski	Head of HCP Marketing and Sales Training
Susan Patricia Park A.C.A., A.C.I.S., ACSA, AGIA, B.Com., C.A., F Fin	Company Secretary